Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Cost of Revenue: 2012-2024

Historic Cost of Revenue for Ani Pharmaceuticals (ANIP) over the last 13 years, with Dec 2024 value amounting to $250.2 million.

  • Ani Pharmaceuticals' Cost of Revenue rose 48.06% to $93.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $321.3 million, marking a year-over-year increase of 43.86%. This contributed to the annual value of $250.2 million for FY2024, which is 37.85% up from last year.
  • As of FY2024, Ani Pharmaceuticals' Cost of Revenue stood at $250.2 million, which was up 37.85% from $181.5 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Cost of Revenue registered a high of $250.2 million during FY2024, and its lowest value of $87.2 million during FY2020.
  • Moreover, its 3-year median value for Cost of Revenue was $181.5 million (2023), whereas its average is $190.2 million.
  • Data for Ani Pharmaceuticals' Cost of Revenue shows a peak YoY soared of 38.01% (in 2020) over the last 5 years.
  • Over the past 5 years, Ani Pharmaceuticals' Cost of Revenue (Yearly) stood at $87.2 million in 2020, then increased by 15.44% to $100.6 million in 2021, then soared by 37.94% to $138.8 million in 2022, then soared by 30.79% to $181.5 million in 2023, then surged by 37.85% to $250.2 million in 2024.